Measuring the symptom burden of lung cancer: The validity and utility of the lung cancer module of the M. D. Anderson symptom inventory

Oncologist

Volumn 16, Issue 2, 2011, Pages 217-227

  Mendoza, Tito R ^a   Shelleywang, Xin ^a   Lu, Charles ^a   Palos, Guadalupe R ^a   Liao, Zhongxing ^a   Mobley, Gary M ^a   Kapoor, Shitij ^b   Cleeland, Charles S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Symptoms assessment validation lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; CANCER GROWTH; CANCER STAGING; CHEMORADIOTHERAPY; COGNITIVE DEBRIEFING; COHORT ANALYSIS; CONCURRENT VALIDITY; CONSTIPATION; CONSTRUCT VALIDITY; CONTENT VALIDITY; CONTROLLED STUDY; COUGHING; CRITERION RELATED VALIDITY; DISEASE SEVERITY; FEMALE; HUMAN; INTERNAL CONSISTENCY; KARNOFSKY PERFORMANCE STATUS; KNOWN GROUP VALIDITY; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; M D ANDERSON SYMPTOM INVENTORY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOMETRY; PSYCHOTHERAPY; SENSITIVITY AND SPECIFICITY; SHORT FORM 12; SORE THROAT; SYMPTOM; TEST RETEST RELIABILITY; VALIDITY;

COMORBIDITY; CONSTIPATION; COST OF ILLNESS; FACTOR ANALYSIS, STATISTICAL; HEALTH STATUS INDICATORS; HUMANS; LUNG NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); PHARYNGITIS; PSYCHOMETRICS; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SICKNESS IMPACT PROFILE;

EID: 79952614928     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0193     Document Type: Article

References (36)

1. Cleeland CS. Symptom burden: multiple symptoms and their impact as patient- reported outcomes. J Natl Cancer Inst Monogr 2007;37:16-21.
2. Soni MK, Cella D, Masters GA et al. The validity and clinical utility of symptom monitoring in advanced lung cancer: a literature review. Clin Lung Cancer 2002;4:153-160.
3. Cella D. Quality of life considerations in patients with advanced lung cancer. Semin Oncol 2004;31(6 suppl 11):16-20.
4. Sarna L, Riedinger MS. Assessment of quality of life and symptom improvement in lung cancer clinical trials. Semin Oncol 2004;31(3 suppl 9):1-10.
5. Wang XS, Shi Q, Lu C et al. Prognostic value of symptom burden for overall survival in patients receiving chemotherapy for advanced nonsmall cell lung cancer. Cancer 2010;116:137-145.
6. Glare PA, Sinclair CT. Palliative medicine review: prognostication. J Palliat Med 2008;11:84-103.
7. Gotay CC, Kawamoto CT, Bottomley A et al. The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol 2008; 26:1355-1363.
8. Cella DF, Bonomi AE, Lloyd SR et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 1995;12:199-220.
9. Bergman B, Aaronson NK, Ahmedzai S et al. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer 1994;30A:635-642.
10. Kirkova J, Davis MP, Walsh D et al. Cancer symptom assessment instruments: a systematic review. J Clin Oncol 2006;24:1459-1473.
11. Hollen PJ, Gralla RJ, Kris MG et al. Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS). Eur J Cancer 1993;29A(suppl 1):S51-S58.
12. Cleeland CS, Mendoza TR, Wang XS et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer 2000;89:1634-1646.
13. Armstrong TS, Mendoza T, Gning I et al. Validation of the M. D. Anderson Symptom Inventory brain tumor module (MDASI-BT). J Neurooncol 2006;80:27-35.
14. Gning I, Trask PC, Mendoza TR et al. Development and initial validation of the thyroid cancer module of the M. D. Anderson Symptom Inventory. Oncology 2009;76:59-68.
15. Rosenthal DI, Mendoza TR, Chambers MS et al. Measuring head and neck cancer symptom burden: The development and validation of the M. D. Anderson Symptom Inventory, head and neck module. Head Neck 2007;29:923-931.
16. Wang XS, Williams LA, Eng C et al. Validation and application of a module of the M. D. Anderson Symptom Inventory for measuring multiple symptoms in patients with gastrointestinal cancer (the MDASI-GI). Cancer 2010;116:2053-2063.
17. Fadol A, Mendoza T, Gning I et al. Psychometric testing of the MDASIHF: a symptom assessment instrument for patients with cancer and concurrent heart failure. J Card Fail 2008;14:497-507.
18. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
19. Serlin RC, Mendoza TR, NakamuraYet al. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 1995;61:277-284.
20. Ware J Jr., Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220-233.
21. Statistical Package for the Social Sciences, version 16.0. Chicago: SPSS, Inc., 2007.
22. Nunnally JC, Bernstein IH. Psychometric Theory, 3rd ed. New York: McGraw-Hill, 1994.
23. Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd ed. Hillsdale, NJ: Lawrence Earlbaum Associates, 1988.
24. Cohen J. A power primer. Psychol Bull 1992;112:155-159.
25. Sloan JA, Vargas-Chanes D, Kamath CC et al. Detecting worms, ducks, and elephants: a simple approach for defining clinically relevant effects in quality-of-life measures. J Cancer Integr Med 2003;1:41-47.
26. Mendoza TR, Wang XS, Cleeland CS et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 1999; 85:1186-1196.
27. U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research et al. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. Washington, DC: U.S. Department of Health and Human Services, 2009. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071975.pdf. Accessed December 18, 2009.
28. Lin CC, Chang AP, Cleeland CS et al. Taiwanese version of the M. D. Anderson Symptom Inventory: symptom assessment in cancer patients. J Pain Symptom Manage 2007;33:180-188.
29. Mystakidou K, Cleeland C, Tsilika E et al. Greek M. D. Anderson Symptom Inventory: validation and utility in cancer patients. Oncology 2004;67:203-210.
30. Nejmi M, Cleeland CS, Mendoza TR et al. Validation and application of the Arabic version of the M. D. Anderson Symptom Inventory (MDASI-A) in Moroccan patients with cancer. J Pain Symptom Manage 2010;40:75-86.
31. Okuyama T, Wang XS, Akechi T et al. Japansese version of the M. D. Anderson Symptom Inventory: a validation study. J Pain Symptom Manage 2003;26:1093-1104.
32. Wang XS, Wang Y, Guo H et al. Chinese version of the M. D. Anderson Symptom Inventory: validation and application of symptom measurement in cancer patients. Cancer 2004;101:1890-1901.
33. Wang XS, Laudico AV, Guo H et al. Filipino version of the M. D. Anderson Symptom Inventory: validation and multisymptom measurement in cancer patients. J Pain Symptom Manage 2006;31:542-552.
34. Yun YH, Mendoza TR, Kang IO et al. Validation study of the Korean version of the M. D. Anderson Symptom Inventory. J Pain Symptom Manage 2006;31:345-352.
35. Wang XS, Cleeland CS, Mendoza TR et al. Impact of cultural and linguistic factors on symptom reporting by patients with cancer. J Natl Cancer Inst 2010;102:732-738.
36. Wang XS, Fairclough DL, Liao Z et al. Longitudinal study of the relationship between chemoradiation therapy for non-small-cell lung cancer and patient symptoms. J Clin Oncol 2006;24:4485-4491.